The European Investment Bank (EIB) is providing €20 million in venture-debt financing to German medical-technology company Protembis to develop a next-generation device for protecting the brains of ...

InspireMD Inc ($NSPR) announced an update on their ongoing clinical study. InspireMD Inc. has announced a pivotal clinical study titled ...

NEW YORK & AACHEN, Germany--(BUSINESS WIRE)--Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the ...

Please provide your email address to receive an email when new articles are posted on . In patients having TAVR, cerebral embolic protection reduced risk for periprocedural stroke in patients from the ...

Protembis GmbH received €20 million (US$21.66 million) in financing from the European Investment Bank to develop its cerebral embolic protection system, Protembo. The intra-aortic filter device ...

AACHEN, Germany--(BUSINESS WIRE)--The Managing Directors and founders of Protembis GmbH, Karl von Mangoldt and Conrad Rasmus, have successfully closed a Series A financing round in a structured ...

NEW YORK, NY—Yet again, use of the Sentinel cerebral protection system (Boston Scientific) has not been shown to significantly improve clinical outcomes for patients undergoing TAVI, according to the ...

Since your nervous system needs to be in a space of safety to regulate and allow the body to properly heal, taking the time and care to integrate the brain science behind chronic conditions is a ...

The first day at the recently concluded Transcatheter Cardiovascular Therapies (TCT) meeting in Washington, D.C., was reportedly heavily focused on TAVR - transcatheter aortic valve replacement ...

Only CEP Trial Designed as a Superiority Trial using DW-MRI to Demonstrate Effectiveness Against the Currently Approved Sentinel Device NEW YORK & AACHEN, Germany–(BUSINESS WIRE)–April 2, 2024– ...